visitant ::
identificació
|
|||||||||||||||
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections : |
Data: | 2020 |
Resum: | This study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31. 9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3. 07, 95% confidence interval (CI), 1. 73-5. 46), septic shock (HR 1. 75, 95% CI, 1. 12-2. 75), and higher Pitt scores (one-point increments; HR 1. 25, 95% CI, 1. 12-1. 38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0. 39, 95% CI, 0. 24-0. 62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0. 56, 95% CI, 0. 33-0. 93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources. |
Ajuts: | Instituto de Salud Carlos III PI16/00669 Instituto de Salud Carlos III PI17/00251 Instituto de Salud Carlos III CM18/00047 Instituto de Salud Carlos III RD16/0016/0015 |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Llengua: | Anglès |
Document: | Estudi clínic ; recerca ; Versió publicada |
Matèria: | Extensively drug-resistant Pseudomonas aeruginosa ; Multidrug resistance ; High-risk clones ; Combined antimicrobial therapy ; Bacteremia ; Outcome |
Publicat a: | Journal of clinical medicine, Vol. 9 Núm. 2 (2020) , p. 514, ISSN 2077-0383 |
14 p, 627.0 KB |